Mortality of IgA nephropathy patients: a single center experience over 30 years
Research on the prognosis of IgA nephropathy (IgAN) has focused on renal survival, with little information being available on patient survival. Hence, this investigation aimed to explore long-term patient outcome in IgAN patients. Clinical and pathological characteristics at the time of renal biopsy...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-12, Vol.7 (12), p.e51225-e51225 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e51225 |
|---|---|
| container_issue | 12 |
| container_start_page | e51225 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Lee, Hajeong Kim, Dong Ki Oh, Kook-Hwan Joo, Kwon Wook Kim, Yon Su Chae, Dong-Wan Kim, Suhnggwon Chin, Ho Jun |
| description | Research on the prognosis of IgA nephropathy (IgAN) has focused on renal survival, with little information being available on patient survival. Hence, this investigation aimed to explore long-term patient outcome in IgAN patients. Clinical and pathological characteristics at the time of renal biopsy were reviewed in 1,364 IgAN patients from 1979 to 2008. The outcomes were patient death and end stage renal disease (ESRD) progression. Overall, 71 deaths (5.3%) and 277 cases of ESRD (20.6%) occurred during 13,916 person-years. Ten-, 20-, and 30-year patient survival rates were 96.3%, 91.8%, and 82.7%, respectively. More than 50% patient deaths occurred without ESRD progression. Overall mortality was elevated by 43% from an age/sex-matched general population (GP) (standardized mortality ratio [SMR], 1.43; 95% confidence interval [CI], 1.04-1.92). Men had comparable mortality to GP (SMR, 1.22; 95% CI, 0.82-1.75), but, in women, the mortality rate was double (SMR, 2.17; 95% CI, 1.21-3.57). Patients with renal risk factors such as initial renal dysfunction (estimated glomerular filgration rate |
| doi_str_mv | 10.1371/journal.pone.0051225 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1326749029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477090388</galeid><doaj_id>oai_doaj_org_article_0721f2e0b8ab42dd83d3e3b2092b2c00</doaj_id><sourcerecordid>A477090388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-733b71332276572a8a1f80c04e5cfb4b8f90565fc5ae3b8d2d743c65dfb7da823</originalsourceid><addsrcrecordid>eNqNkltr2zAUx83YWC_bNxibYTC2h2S6WJa8h0EouwQ6Aru9ClmWHAXFciW5NN--SuOWePRhGGRdfud_dI7-WfYKgjnEFH7cuMF3ws5716k5AAQiRJ5kp7DCaFYigJ8ezU-ysxA2CcKsLJ9nJwgjVJKSnWarH85HYU3c5U7ny3aRd6pfe9eLuN7laTSqi-FTLvJgutaqXKa18rm66ZVPZ1Ll7jqtMch3SvjwInumhQ3q5fg_z_58_fL74vvscvVtebG4nElKWJxRjGsKcboGLQlFggmoGZCgUETquqiZrgApiZZEKFyzBjW0wLIkja5pIxjC59mbg25vXeBjLwKHGJW0qACqErE8EI0TG957sxV-x50w_G7D-ZYLH420igOKoEYK1EzUBWoahhuc0iJQoRpJAJLW5zHbUG9Vs--BF3YiOj3pzJq37ppjAgvIWBJ4Pwp4dzWoEPnWBKmsFZ1yQ7o3wjShAO0re_sP-nh1I9WKVIDptEt55V6ULwpKQQXwXdr5I1T6GrU1MhlHm7Q_CfgwCUhMVDexFUMIfPnr5_-zq79T9t0Ru1bCxnVwdojGdWEKFgdQeheCV_qhyRDwve_vu8H3vuej71PY6-MHegi6Nzq-BVkc--Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1326749029</pqid></control><display><type>article</type><title>Mortality of IgA nephropathy patients: a single center experience over 30 years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lee, Hajeong ; Kim, Dong Ki ; Oh, Kook-Hwan ; Joo, Kwon Wook ; Kim, Yon Su ; Chae, Dong-Wan ; Kim, Suhnggwon ; Chin, Ho Jun</creator><contributor>Baradaran, Hamid Reza</contributor><creatorcontrib>Lee, Hajeong ; Kim, Dong Ki ; Oh, Kook-Hwan ; Joo, Kwon Wook ; Kim, Yon Su ; Chae, Dong-Wan ; Kim, Suhnggwon ; Chin, Ho Jun ; Baradaran, Hamid Reza</creatorcontrib><description>Research on the prognosis of IgA nephropathy (IgAN) has focused on renal survival, with little information being available on patient survival. Hence, this investigation aimed to explore long-term patient outcome in IgAN patients. Clinical and pathological characteristics at the time of renal biopsy were reviewed in 1,364 IgAN patients from 1979 to 2008. The outcomes were patient death and end stage renal disease (ESRD) progression. Overall, 71 deaths (5.3%) and 277 cases of ESRD (20.6%) occurred during 13,916 person-years. Ten-, 20-, and 30-year patient survival rates were 96.3%, 91.8%, and 82.7%, respectively. More than 50% patient deaths occurred without ESRD progression. Overall mortality was elevated by 43% from an age/sex-matched general population (GP) (standardized mortality ratio [SMR], 1.43; 95% confidence interval [CI], 1.04-1.92). Men had comparable mortality to GP (SMR, 1.22; 95% CI, 0.82-1.75), but, in women, the mortality rate was double (SMR, 2.17; 95% CI, 1.21-3.57). Patients with renal risk factors such as initial renal dysfunction (estimated glomerular filgration rate <60 ml/min per 1.73 m(2); SMR, 1.70; 95% CI, 1.13-2.46), systolic blood pressure ≥ 140 mmHg (SMR, 1.88; 95% CI, 1.19-2.82) or proteinuria ≥ 1 g/day (SMR, 1.66; 95% CI, 1.16-2.29) had an elevated mortality rate. Patients with preserved renal function, normotension, and proteinuria <1 g/day, however, had a similar mortality rate to GP. When risk stratification was performed by counting the number of major risk factors present at diagnosis, low-risk IgAN patients had a mortality rate equal to that of GP, whereas high-risk patients had a mortality rate higher than that of GP. This investigation demonstrated that overall mortality in IgAN patients was higher than that of GP. Women and patients with renal risk factors had a higher mortality than that of GP, Therefore, strategies optimized to alleviate major renal risk factors are warranted to reduce patient mortality.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0051225</identifier><identifier>PMID: 23226568</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Biology ; Biopsy ; Blood pressure ; Cause of Death ; Chronic kidney failure ; Confidence intervals ; Demography ; Development and progression ; Disease Progression ; Fatalities ; Female ; Glomerulonephritis, IGA - drug therapy ; Glomerulonephritis, IGA - mortality ; Glomerulonephritis, IGA - pathology ; Humans ; IgA nephropathy ; Immunoglobulin A ; Immunosuppressive Agents - pharmacology ; Immunosuppressive Agents - therapeutic use ; Kidney - drug effects ; Kidney - pathology ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - mortality ; Kidney Failure, Chronic - pathology ; Kidney transplantation ; Lupus ; Male ; Medicine ; Middle Aged ; Mortality ; Multivariate Analysis ; Patient outcomes ; Patients ; Prognosis ; Proportional Hazards Models ; Proteinuria ; Renal function ; Republic of Korea - epidemiology ; Risk analysis ; Risk factors ; Risk groups ; Studies ; Survival ; Survival Analysis ; Young Adult</subject><ispartof>PloS one, 2012-12, Vol.7 (12), p.e51225-e51225</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2012 Lee et al 2012 Lee et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-733b71332276572a8a1f80c04e5cfb4b8f90565fc5ae3b8d2d743c65dfb7da823</citedby><cites>FETCH-LOGICAL-c758t-733b71332276572a8a1f80c04e5cfb4b8f90565fc5ae3b8d2d743c65dfb7da823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514188/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514188/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23226568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Baradaran, Hamid Reza</contributor><creatorcontrib>Lee, Hajeong</creatorcontrib><creatorcontrib>Kim, Dong Ki</creatorcontrib><creatorcontrib>Oh, Kook-Hwan</creatorcontrib><creatorcontrib>Joo, Kwon Wook</creatorcontrib><creatorcontrib>Kim, Yon Su</creatorcontrib><creatorcontrib>Chae, Dong-Wan</creatorcontrib><creatorcontrib>Kim, Suhnggwon</creatorcontrib><creatorcontrib>Chin, Ho Jun</creatorcontrib><title>Mortality of IgA nephropathy patients: a single center experience over 30 years</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Research on the prognosis of IgA nephropathy (IgAN) has focused on renal survival, with little information being available on patient survival. Hence, this investigation aimed to explore long-term patient outcome in IgAN patients. Clinical and pathological characteristics at the time of renal biopsy were reviewed in 1,364 IgAN patients from 1979 to 2008. The outcomes were patient death and end stage renal disease (ESRD) progression. Overall, 71 deaths (5.3%) and 277 cases of ESRD (20.6%) occurred during 13,916 person-years. Ten-, 20-, and 30-year patient survival rates were 96.3%, 91.8%, and 82.7%, respectively. More than 50% patient deaths occurred without ESRD progression. Overall mortality was elevated by 43% from an age/sex-matched general population (GP) (standardized mortality ratio [SMR], 1.43; 95% confidence interval [CI], 1.04-1.92). Men had comparable mortality to GP (SMR, 1.22; 95% CI, 0.82-1.75), but, in women, the mortality rate was double (SMR, 2.17; 95% CI, 1.21-3.57). Patients with renal risk factors such as initial renal dysfunction (estimated glomerular filgration rate <60 ml/min per 1.73 m(2); SMR, 1.70; 95% CI, 1.13-2.46), systolic blood pressure ≥ 140 mmHg (SMR, 1.88; 95% CI, 1.19-2.82) or proteinuria ≥ 1 g/day (SMR, 1.66; 95% CI, 1.16-2.29) had an elevated mortality rate. Patients with preserved renal function, normotension, and proteinuria <1 g/day, however, had a similar mortality rate to GP. When risk stratification was performed by counting the number of major risk factors present at diagnosis, low-risk IgAN patients had a mortality rate equal to that of GP, whereas high-risk patients had a mortality rate higher than that of GP. This investigation demonstrated that overall mortality in IgAN patients was higher than that of GP. Women and patients with renal risk factors had a higher mortality than that of GP, Therefore, strategies optimized to alleviate major renal risk factors are warranted to reduce patient mortality.</description><subject>Adult</subject><subject>Biology</subject><subject>Biopsy</subject><subject>Blood pressure</subject><subject>Cause of Death</subject><subject>Chronic kidney failure</subject><subject>Confidence intervals</subject><subject>Demography</subject><subject>Development and progression</subject><subject>Disease Progression</subject><subject>Fatalities</subject><subject>Female</subject><subject>Glomerulonephritis, IGA - drug therapy</subject><subject>Glomerulonephritis, IGA - mortality</subject><subject>Glomerulonephritis, IGA - pathology</subject><subject>Humans</subject><subject>IgA nephropathy</subject><subject>Immunoglobulin A</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Kidney Failure, Chronic - pathology</subject><subject>Kidney transplantation</subject><subject>Lupus</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Proteinuria</subject><subject>Renal function</subject><subject>Republic of Korea - epidemiology</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Studies</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNkltr2zAUx83YWC_bNxibYTC2h2S6WJa8h0EouwQ6Aru9ClmWHAXFciW5NN--SuOWePRhGGRdfud_dI7-WfYKgjnEFH7cuMF3ws5716k5AAQiRJ5kp7DCaFYigJ8ezU-ysxA2CcKsLJ9nJwgjVJKSnWarH85HYU3c5U7ny3aRd6pfe9eLuN7laTSqi-FTLvJgutaqXKa18rm66ZVPZ1Ll7jqtMch3SvjwInumhQ3q5fg_z_58_fL74vvscvVtebG4nElKWJxRjGsKcboGLQlFggmoGZCgUETquqiZrgApiZZEKFyzBjW0wLIkja5pIxjC59mbg25vXeBjLwKHGJW0qACqErE8EI0TG957sxV-x50w_G7D-ZYLH420igOKoEYK1EzUBWoahhuc0iJQoRpJAJLW5zHbUG9Vs--BF3YiOj3pzJq37ppjAgvIWBJ4Pwp4dzWoEPnWBKmsFZ1yQ7o3wjShAO0re_sP-nh1I9WKVIDptEt55V6ULwpKQQXwXdr5I1T6GrU1MhlHm7Q_CfgwCUhMVDexFUMIfPnr5_-zq79T9t0Ru1bCxnVwdojGdWEKFgdQeheCV_qhyRDwve_vu8H3vuej71PY6-MHegi6Nzq-BVkc--Q</recordid><startdate>20121204</startdate><enddate>20121204</enddate><creator>Lee, Hajeong</creator><creator>Kim, Dong Ki</creator><creator>Oh, Kook-Hwan</creator><creator>Joo, Kwon Wook</creator><creator>Kim, Yon Su</creator><creator>Chae, Dong-Wan</creator><creator>Kim, Suhnggwon</creator><creator>Chin, Ho Jun</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20121204</creationdate><title>Mortality of IgA nephropathy patients: a single center experience over 30 years</title><author>Lee, Hajeong ; Kim, Dong Ki ; Oh, Kook-Hwan ; Joo, Kwon Wook ; Kim, Yon Su ; Chae, Dong-Wan ; Kim, Suhnggwon ; Chin, Ho Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-733b71332276572a8a1f80c04e5cfb4b8f90565fc5ae3b8d2d743c65dfb7da823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Biology</topic><topic>Biopsy</topic><topic>Blood pressure</topic><topic>Cause of Death</topic><topic>Chronic kidney failure</topic><topic>Confidence intervals</topic><topic>Demography</topic><topic>Development and progression</topic><topic>Disease Progression</topic><topic>Fatalities</topic><topic>Female</topic><topic>Glomerulonephritis, IGA - drug therapy</topic><topic>Glomerulonephritis, IGA - mortality</topic><topic>Glomerulonephritis, IGA - pathology</topic><topic>Humans</topic><topic>IgA nephropathy</topic><topic>Immunoglobulin A</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Kidney Failure, Chronic - pathology</topic><topic>Kidney transplantation</topic><topic>Lupus</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Proteinuria</topic><topic>Renal function</topic><topic>Republic of Korea - epidemiology</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Studies</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hajeong</creatorcontrib><creatorcontrib>Kim, Dong Ki</creatorcontrib><creatorcontrib>Oh, Kook-Hwan</creatorcontrib><creatorcontrib>Joo, Kwon Wook</creatorcontrib><creatorcontrib>Kim, Yon Su</creatorcontrib><creatorcontrib>Chae, Dong-Wan</creatorcontrib><creatorcontrib>Kim, Suhnggwon</creatorcontrib><creatorcontrib>Chin, Ho Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hajeong</au><au>Kim, Dong Ki</au><au>Oh, Kook-Hwan</au><au>Joo, Kwon Wook</au><au>Kim, Yon Su</au><au>Chae, Dong-Wan</au><au>Kim, Suhnggwon</au><au>Chin, Ho Jun</au><au>Baradaran, Hamid Reza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality of IgA nephropathy patients: a single center experience over 30 years</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-12-04</date><risdate>2012</risdate><volume>7</volume><issue>12</issue><spage>e51225</spage><epage>e51225</epage><pages>e51225-e51225</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Research on the prognosis of IgA nephropathy (IgAN) has focused on renal survival, with little information being available on patient survival. Hence, this investigation aimed to explore long-term patient outcome in IgAN patients. Clinical and pathological characteristics at the time of renal biopsy were reviewed in 1,364 IgAN patients from 1979 to 2008. The outcomes were patient death and end stage renal disease (ESRD) progression. Overall, 71 deaths (5.3%) and 277 cases of ESRD (20.6%) occurred during 13,916 person-years. Ten-, 20-, and 30-year patient survival rates were 96.3%, 91.8%, and 82.7%, respectively. More than 50% patient deaths occurred without ESRD progression. Overall mortality was elevated by 43% from an age/sex-matched general population (GP) (standardized mortality ratio [SMR], 1.43; 95% confidence interval [CI], 1.04-1.92). Men had comparable mortality to GP (SMR, 1.22; 95% CI, 0.82-1.75), but, in women, the mortality rate was double (SMR, 2.17; 95% CI, 1.21-3.57). Patients with renal risk factors such as initial renal dysfunction (estimated glomerular filgration rate <60 ml/min per 1.73 m(2); SMR, 1.70; 95% CI, 1.13-2.46), systolic blood pressure ≥ 140 mmHg (SMR, 1.88; 95% CI, 1.19-2.82) or proteinuria ≥ 1 g/day (SMR, 1.66; 95% CI, 1.16-2.29) had an elevated mortality rate. Patients with preserved renal function, normotension, and proteinuria <1 g/day, however, had a similar mortality rate to GP. When risk stratification was performed by counting the number of major risk factors present at diagnosis, low-risk IgAN patients had a mortality rate equal to that of GP, whereas high-risk patients had a mortality rate higher than that of GP. This investigation demonstrated that overall mortality in IgAN patients was higher than that of GP. Women and patients with renal risk factors had a higher mortality than that of GP, Therefore, strategies optimized to alleviate major renal risk factors are warranted to reduce patient mortality.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23226568</pmid><doi>10.1371/journal.pone.0051225</doi><tpages>e51225</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-12, Vol.7 (12), p.e51225-e51225 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1326749029 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adult Biology Biopsy Blood pressure Cause of Death Chronic kidney failure Confidence intervals Demography Development and progression Disease Progression Fatalities Female Glomerulonephritis, IGA - drug therapy Glomerulonephritis, IGA - mortality Glomerulonephritis, IGA - pathology Humans IgA nephropathy Immunoglobulin A Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Kidney - drug effects Kidney - pathology Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - mortality Kidney Failure, Chronic - pathology Kidney transplantation Lupus Male Medicine Middle Aged Mortality Multivariate Analysis Patient outcomes Patients Prognosis Proportional Hazards Models Proteinuria Renal function Republic of Korea - epidemiology Risk analysis Risk factors Risk groups Studies Survival Survival Analysis Young Adult |
| title | Mortality of IgA nephropathy patients: a single center experience over 30 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A36%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20of%20IgA%20nephropathy%20patients:%20a%20single%20center%20experience%20over%2030%20years&rft.jtitle=PloS%20one&rft.au=Lee,%20Hajeong&rft.date=2012-12-04&rft.volume=7&rft.issue=12&rft.spage=e51225&rft.epage=e51225&rft.pages=e51225-e51225&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0051225&rft_dat=%3Cgale_plos_%3EA477090388%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1326749029&rft_id=info:pmid/23226568&rft_galeid=A477090388&rft_doaj_id=oai_doaj_org_article_0721f2e0b8ab42dd83d3e3b2092b2c00&rfr_iscdi=true |